On May 22, the FDA granted approval to mepolizumab as a biologic add-on maintenance treatment for adults with inadequately controlled COPD. Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University and Director of the Temple Lung Center, spoke with MedPage Today, Healio and AJMCTV about how the recent approval of mepolizumab may improve outcomes for patients and transform treatment of COPD.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH